Cardiovascular medication use following percutaneous coronary intervention: The Australian experience

Cardiovascular Therapeutics

Volumn 32, Issue 2, 2014, Pages 47-51

  Cole, Justin A ^a,b   Brennan, Angela L ^a,b   Ajani, Andrew E ^a,c,d   Yan, Bryan P ^a,e   Duffy, Stephen J ^a,b   Loane, Philippa ^a   Reid, Christopher M ^a   Yudi, Matias B ^c   New, Gishel ^a,f   Black, Alexander ^a,c,g,h   Shaw, James ^b   Clark, David J ⁱ   Andrianopoulos, Nick ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f BOX HILL HOSPITAL   (Australia)

^g GEELONG HOSPITAL   (Australia)

^h DEAKIN UNIVERSITY   (Australia)

ⁱ AUSTIN HOSPITAL   (Australia)

Author keywords

Guidelines; Medications; Percutaneous coronary intervention; Registry

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG USE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; TREATMENT OUTCOME;

GUIDELINES; MEDICATIONS; PERCUTANEOUS CORONARY INTERVENTION; REGISTRY;

AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; VICTORIA;

EID: 84896084386     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12060     Document Type: Article

References (27)

1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the national heart, lung, and blood institute. Circulation 2006;113:2363-2372.
2. Davidson P, Stocks N, Aggarwal A, et al. Reducing risk in heart disease: An expert guide to clinical practice for secondary prevention of coronary heart disease, Updated 2012. National heart foundation of Australia and Cardiac Society of Australia and New Zealand 2012.
3. Australian Resuscitation Council NZRC. Acute coronary syndromes: Initial medical therapy. ARC and NZRC guideline 2011. Emerg Med Australas 2011;23:308-311.
4. Giorda C, Maggini M, Alegiani SS, Turco S, Raschetti R. Secondary prevention of coronary artery disease in high-risk diabetic patients. Nutr Metab Cardiovasc Dis 2003;13:238-243.
5. Joynt KE, Huynh L, Amerena JV, et al. Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes. Heart 2009;95:1442-1448.
6. Pheatt N, Brindis G, Levin E. Putting heart disease guidelines into practice: Kaiser permanente leads the way. The Permanente Journal 2003;7:18-23.
7. Ajani AE, Szto G, Duffy SJ, et al. The foundation and launch of the Melbourne interventional group: A collaborative interventional cardiology project. Heart Lung Circ 2006;15:44-47.
8. McNeil JJ, Evans SM, Johnson NP, Cameron PA. Clinical-quality registries: Their role in quality improvement. Med J Aust 2010;192:244-245.
9. Skillington P. A national cardiac surgery database: Current achievements and future challenges. Heart Lung Circ 2001;10:S2-S4.
10. Graves SE, Davidson D, Ingerson L, et al. The Australian orthopaedic association national joint replacement registry. Med J Aust 2004;180:S31-S34.
11. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;4:87-90.
12. Zeymer U, James S, Berkenboom G, et al. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev Cardiol 2013;20:218-228.
13. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Euroaspire III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-137.
14. Lee JH, Yang DH, Park HS, et al. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea acute myocardial infarction registry: Prescription rate, predictors, and prognostic value. Am Heart J 2010;159:1012-1019.
15. Prugger C, Heidrich J, Wellmann J, et al. Trends in cardiovascular risk factors among patients with coronary heart disease: Results from the Euroaspire I, II, and III surveys in the Munster region. Dtsch Arztebl Int 2012;109:303-310.
16. Boden WE, Flather MD, Bhatt DL. Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: Putting the charisma trial into therapeutic perspective. Cardiovasc Drugs Ther 2010;24:207-216.
17. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e637S-e668S.
18. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-1041e1.
19. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: Frequency, predictors and associations with death and myocardial infarction-a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011;32:2376-2386.
20. Prugger C, Keil U, Wellmann J, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: Results from the Euroaspire III survey. J Hypertens 2011;29:1641-1648.
21. Murphy BM, Worcester MU, Goble AJ, et al. Lifestyle and physiological risk factor profiles six weeks after an acute cardiac event: Are patients achieving recommended targets for secondary prevention? Heart Lung Circ 2011;20:446-451.
22. Nguyen HL, Goldberg RJ, Gore JM, et al. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: Perspectives from a multinational registry. Coron Artery Dis 2010;21:336-344.
23. Dallongevillle J, De Bacquer D, Heidrich J, et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart 2010;96:1744-1749.
24. Onuma Y, Kukreja N, Ramcharitar S, Hochadel M, Gitt A, Serruys P. Interventional treatment in diabetics in the era of drug-eluting stents and compliance to the ESC guidelines: Lessons learned from the Euro heart survey programme. EuroIntervention 2009;4:578-587.
25. Aliprandi-Costa B, Ranasinghe I, Chow V, et al. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000-2007. Med J Aust 2011;195:116-121.
26. Bakhai A, Ferrieres J, Iniguez A, Schmitt C, Sartral M, Belger M, Zeymer U. International data on supportive therapies at 1 year in acute coronary syndrome patients undergoing PCI: Results from the Aptor study. Eur J Cardiovasc Prev Rehabil 2011;18:518-525.
27. Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D, Graham I. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prev Cardiol 2013;20:686-691.